Improving Outcomes in Chronic Kidney Disease: Optimizing Management of Cardiovascular Diseases [CME/
Advertisement
Advertisement
Trending on AJMC
1
5 August FDA Approvals Marked by Novelty, Pushback
2
Newer Agents, New Advantages: Brexpiprazole, Cariprazine, and Lumateperone in MDD
3
Dosing, Tolerability, and Formulary Impact: Aripiprazole and Quetiapine XR in MDD
4
Cross-Trial Vitiligo Data: What Payers Can and Can't Compare
5